About: Recombinant Vaccines against T. gondii: Comparison between Homologous and Heterologous Vaccination Protocols Using Two Viral Vectors Expressing SAG1

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Recombinant Vaccines against T. gondii: Comparison between Homologous and Heterologous Vaccination Protocols Using Two Viral Vectors Expressing SAG1 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Recombinant Vaccines against T. gondii: Comparison between Homologous and Heterologous Vaccination Protocols Using Two Viral Vectors Expressing SAG1
Creator	Araú, Rica Brazil, Caetano, Braulia Casé Rio, M Colina, Janaína Cruz, Oswaldo Fonseca, Flavio Gazzinelli, Ricardo Horizonte, Belo Mendes, Jo Pesquisas, De Rachou, René Rbara, Bá
Source	PMC
abstract	The use of recombinant viral vectors expressing T. gondii antigens is a safe and efficient approach to induce immune response against the parasite and a valuable tool for vaccine development. We have previously protected mice from toxoplasmosis by immunizing the animals with an adenovirus expressing the protein SAG1 (AdSAG1) of T. gondii. We are now looking for ways to improve the vaccination strategy and enhance protection. One limitation of homologous vaccinations (sequential doses of the same vector) is induction of anti-vector immune response that blocks cell transduction, restricts transgene expression and, consequently, compromises the overall outcome of vaccination. One way to avert the effects of anti-vector response is to use different viruses in prime and boost (heterologous vaccination). Bearing this in mind, we generated a modified Vaccinia Virus Ankara encoding SAG1 (MVASAG1), to be tested as boost agent after prime with AdSAG1. Although minor differences were observed in the magnitude of the anti-SAG1 immune response induced by each vaccination protocol, the heterologous immunization with AdSAG1 followed by MVASAG1 resulted in improved capacity to control brain cyst formation in a model of chronic toxoplasmosis in C57BL/6 mice.
has issue date	2013-05-15(xsd:dateTime)
bibo:doi	10.1371/journal.pone.0063201
bibo:pmid	23690999
has license	cc-by
sha1sum (hex)	6fcc000ecf39dd1da69d94d8cd764790ce96aaba
schema:url	https://doi.org/10.1371/journal.pone.0063201
resource representing a document's title	Recombinant Vaccines against T. gondii: Comparison between Homologous and Heterologous Vaccination Protocols Using Two Viral Vectors Expressing SAG1
has PubMed Central identifier	PMC3654925
has PubMed identifier	23690999
schema:publication	PLoS One
resource representing a document's body	covid:6fcc000ecf39dd1da69d94d8cd764790ce96aaba#body_text
is schema:about of	named entity 'improved' named entity 'One' named entity 'heterologous' named entity 'Ankara' named entity 'tested' named entity 'Although' named entity 'Expressing' named entity 'VACCINATIONS' named entity 'PREVIOUSLY' named entity 'WAY' named entity 'MODEL OF' named entity 'STRATEGY' named entity 'SAG1' named entity 'GENERATED' named entity 'VACCINATION' named entity 'MAGNITUDE' named entity 'SAFE' named entity 'USE OF' named entity 'TOXOPLASMOSIS' named entity 'INDUCED' named entity 'BRAIN CYST' named entity 'DOSES' named entity 'MICE' named entity 'TO CONTROL' named entity 'VECTORS' named entity 'HAVE' named entity 'IMMUNIZATION' named entity 'CHRONIC' named entity 'TESTED' named entity 'RESTRICTS' named entity 'BLOCKS' named entity 'CAPACITY' named entity 'PROTEIN ' named entity 'LIMITATION' named entity 'PROTECTION' named entity 'ENCODING' named entity 'HOMOLOGOUS' named entity 'BEARING' named entity 'USE' named entity 'VACCINE DEVELOPMENT' named entity 'OVERALL' named entity 'PRIME' named entity 'CELL' named entity 'ANIMALS' named entity 'C57BL' named entity 'APPROACH' named entity 'OBSERVED' named entity 'RECOMBINANT' named entity 'HETEROLOGOUS' named entity 'IS A' named entity 'IMMUNE RESPONSE' named entity 'VACCINIA VIRUS ANKARA' named entity 'TRANSGENE EXPRESSION' named entity 'INDUCTION' named entity 'ADENOVIRUS' named entity 'DIFFERENT' named entity 'CYST FORMATION' named entity 'TRANSDUCTION' named entity 'SAG1' named entity 'ENHANCE' named entity 'BOOST' named entity 'COMPROMISES' named entity 'IMPROVED' named entity 'MIND' named entity 'VIRUSES' named entity 'VACCINATION PROTOCOL' named entity 'MODIFIED' named entity 'ANTIGENS' named entity 'LOOKING'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software